David Kerr

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. ncbi request reprint Clinical development of gene therapy for colorectal cancer
    David Kerr
    National Translational Cancer Research Network, Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Nat Rev Cancer 3:615-22. 2003
  2. ncbi request reprint Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer
    David J Kerr
    Oncology Clinical Trials Office, University of Oxford, Oxford, United Kingdom
    N Engl J Med 357:360-9. 2007
  3. ncbi request reprint Capecitabine/irinotecan combination regimens in colorectal cancer
    David J Kerr
    University of Oxford, Department of Clinical Pharmacology, Radcliffe Infirmary, United Kingdom
    Oncology (Williston Park) 16:27-9. 2002
  4. ncbi request reprint Targeting angiogenesis in cancer: clinical development of bevacizumab
    David J Kerr
    Clinical Pharmacology Department, Radcliffe Infirmary, Oxford, UK
    Nat Clin Pract Oncol 1:39-43. 2004
  5. doi request reprint Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer
    Jeremie H Lefevre
    Department of Clinical Pharmacology, Cancer and Immunogenetics Laboratory, University of Oxford, Oxford, UK
    J Hum Genet 57:709-16. 2012
  6. pmc Comprehensive assessment of variation at the transforming growth factor beta type 1 receptor locus and colorectal cancer predisposition
    Luis G Carvajal-Carmona
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom
    Proc Natl Acad Sci U S A 107:7858-62. 2010
  7. ncbi request reprint Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003
    Ray Chan
    Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
    Curr Opin Oncol 16:378-84. 2004
  8. pmc Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN
    Andrew D Beggs
    University of Oxford, Oxford, UK
    Oncotarget 3:1348-55. 2012
  9. pmc Use of multivariate analysis to suggest a new molecular classification of colorectal cancer
    Enric Domingo
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    J Pathol 229:441-8. 2013
  10. ncbi request reprint Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials
    David Kerr
    National Translational Cancer Research Network, University of Oxford, Oxford, United Kingdom
    Oncology (Williston Park) 16:12-5. 2002

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Clinical development of gene therapy for colorectal cancer
    David Kerr
    National Translational Cancer Research Network, Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Nat Rev Cancer 3:615-22. 2003
    ..Techniques include gene replacement, virus-directed enzyme-prodrug therapy, immune manipulation and virotherapy, all of which have entered clinical trials...
  2. ncbi request reprint Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer
    David J Kerr
    Oncology Clinical Trials Office, University of Oxford, Oxford, United Kingdom
    N Engl J Med 357:360-9. 2007
    ..We report on cardiovascular adverse events in patients receiving rofecoxib to reduce rates of recurrence of colorectal cancer...
  3. ncbi request reprint Capecitabine/irinotecan combination regimens in colorectal cancer
    David J Kerr
    University of Oxford, Department of Clinical Pharmacology, Radcliffe Infirmary, United Kingdom
    Oncology (Williston Park) 16:27-9. 2002
    ..Combinations of these agents therefore are being explored in patients with colorectal cancer. This report briefly reviews current and ongoing trials evaluating capecitabine/irinotecan combination regimens in treating this disease...
  4. ncbi request reprint Targeting angiogenesis in cancer: clinical development of bevacizumab
    David J Kerr
    Clinical Pharmacology Department, Radcliffe Infirmary, Oxford, UK
    Nat Clin Pract Oncol 1:39-43. 2004
    ..This review highlights the key clinical trial data with bevacizumab and discusses the reasons for some of the contrasting results seen in different patient studies...
  5. doi request reprint Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer
    Jeremie H Lefevre
    Department of Clinical Pharmacology, Cancer and Immunogenetics Laboratory, University of Oxford, Oxford, UK
    J Hum Genet 57:709-16. 2012
    ..2; 95% confidence interval=1.1-9.5; P=0.04). Rare variants are important risk factors in CRC and, as such, should be systematically assayed alongside common variation in the search for the genetic basis of complex diseases...
  6. pmc Comprehensive assessment of variation at the transforming growth factor beta type 1 receptor locus and colorectal cancer predisposition
    Luis G Carvajal-Carmona
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, United Kingdom
    Proc Natl Acad Sci U S A 107:7858-62. 2010
    ..We conclude that neither genetic variation nor ASE at TGFBR1 is likely to be a major CRC risk factor...
  7. ncbi request reprint Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003
    Ray Chan
    Department of Clinical Pharmacology, University of Oxford, Oxford, United Kingdom
    Curr Opin Oncol 16:378-84. 2004
    ..These new data will be reviewed in the context of previous trials and new observations of novel approaches involving HAC...
  8. pmc Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN
    Andrew D Beggs
    University of Oxford, Oxford, UK
    Oncotarget 3:1348-55. 2012
    ..015). For Ku70, further studies are required to investigate the potential relationship of non-homologous end joining with chromosomal instability. Loss of ATM expression might serve as a biomarker of poor prognosis in colorectal cancer...
  9. pmc Use of multivariate analysis to suggest a new molecular classification of colorectal cancer
    Enric Domingo
    Molecular and Population Genetics Laboratory, Wellcome Trust Centre for Human Genetics, University of Oxford, UK
    J Pathol 229:441-8. 2013
    ..Our classification also showed potentially improved prognostic capabilities, with group 3, and possibly group 1, independently predicting disease-free survival...
  10. ncbi request reprint Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials
    David Kerr
    National Translational Cancer Research Network, University of Oxford, Oxford, United Kingdom
    Oncology (Williston Park) 16:12-5. 2002
    ..These trials will help define the roles of this combination in the treatment of colorectal cancer...
  11. ncbi request reprint The nitroreductase/CB1954 enzyme-prodrug system
    Nicola K Green
    Hybrid Systems Ltd, Littlemore Park, Oxford, UK
    Methods Mol Med 90:459-77. 2004
  12. doi request reprint Cyclin D1 rare variants in UK multiple adenoma and early-onset colorectal cancer patients
    Carolina Bonilla
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, UK
    J Hum Genet 56:58-63. 2011
    ..We conclude that rare variants of CCND1 are risk factors for colorectal cancer, with considerably larger effects than common polymorphisms, and as such should be systematically evaluated in susceptibility studies...
  13. doi request reprint Capecitabine: have we got the dose right?
    Rachel Midgley
    Department of Clinical Pharmacology, University of Oxford, Woodstock Road, Oxford, UK
    Nat Clin Pract Oncol 6:17-24. 2009
    ....
  14. ncbi request reprint Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer
    Leonard W Seymour
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham, UK
    Int J Oncol 34:1629-36. 2009
    ....
  15. ncbi request reprint Adjuvant chemotherapy for stage II colorectal cancer: the time is right!
    Rachel Midgley
    Cancer Research UK Medical Oncology Unit, Churchill Hospital, Headington, Oxford, UK
    Nat Clin Pract Oncol 2:364-9. 2005
    ..Adjuvant therapy for stage II colon cancer has been more controversial. Recent trial data suggest, however, that there is a legitimate case for discussing the advantages and limitations with individual patients...
  16. ncbi request reprint Colorectal cancer
    Shibani Nicum
    Department of Clinical Pharmacology, The University of Oxford, Radcliffe Infirmary, Oxford, UK
    Acta Oncol 42:263-75. 2003
    ..The aim of this review is to provide an overview of the pathogenesis of CRC and to present the evidence base for chemotherapy and some of the novel strategies that are currently being evaluated in phase I and II trials...
  17. ncbi request reprint A trial of adjuvant therapy in colorectal cancer: the VICTOR trial
    Stuart Pendlebury
    Department of Clinical Pharmacology, Oxford University, UK
    Clin Colorectal Cancer 3:58-60. 2003
  18. doi request reprint Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, United Kingdom
    J Clin Oncol 28:4575-80. 2010
    ..The purpose of this study was to test whether the COX-2 inhibitor rofecoxib could reduce recurrence and improve survival when administered in the adjuvant setting of colorectal cancer (CRC)...
  19. ncbi request reprint Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector
    Nicola K Green
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, Oxford, United Kingdom
    Int J Cancer 104:104-12. 2003
    ....
  20. ncbi request reprint Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial
    David J Kerr
    Department of Clinical Pharmacology, University of Oxford, Radcliffe Infirmary, OX2 6HE, Oxford, UK
    Lancet 361:368-73. 2003
    ....
  21. doi request reprint Quinone oxidoreductase-2-mediated prodrug cancer therapy
    Mark R Middleton
    Department of Medical Oncology, Churchill Hospital, Headington, Oxford OX3 7LJ, UK
    Sci Transl Med 2:40ra50. 2010
    ..We detected DNA interstrand cross-links caused by nitroreduced CB1954 in tumor biopsies from treated patients, demonstrating that the activated prodrug exerts its cytotoxic properties through DNA base alkylation...
  22. doi request reprint Biomarkers in early-stage colorectal cancer: ready for prime time?
    David Church
    Oxford Cancer Centre, University of Oxford, Oxford, UK
    Dig Dis 30:27-33. 2012
    ..However, the majority of these studies have been small and retrospective, reporting results that are highly likely to represent false positives. Consequently, their relevance to clinical practice requires definition...
  23. ncbi request reprint Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future
    Ami Sabharwal
    Cancer Research UK, Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Expert Rev Anticancer Ther 7:477-87. 2007
    ..The evolution of chemotherapy use, current practice in the metastatic and adjuvant setting and possible future directions are discussed...
  24. doi request reprint Evolution of nonsurgical therapy for colorectal cancer
    Rachel S Midgley
    Department of Clinical Pharmacology, University of Oxford, Old Road Campus Research Building, Old Road, off Roosevelt Drive, Headington, Oxford, UK
    Nat Clin Pract Gastroenterol Hepatol 6:108-20. 2009
    ....
  25. ncbi request reprint Bevacizumab--current status and future directions
    Rachel Midgley
    Department of Clinical Pharmacology and Cancer Therapeutics, Racliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Ann Oncol 16:999-1004. 2005
    ..Questions still surround optimal dosing and the appropriate selection of patients who are most likely to benefit. Future trials will address these questions and provide further translational insights...
  26. pmc Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes
    Luis G Carvajal-Carmona
    Wellcome Trust Centre for Human Genetics and Department of Clinical Pharmacology, University of Oxford, Oxford, UK
    Hum Mol Genet 20:2879-88. 2011
    ..In addition, caution should be exercised when assigning functionality to candidate genes in regions discovered through GWA analysis...
  27. ncbi request reprint Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?
    David J Kerr
    Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK
    Nat Clin Pract Oncol 3:480-1. 2006
  28. doi request reprint Common variation at the adiponectin locus is not associated with colorectal cancer risk in the UK
    Luis G Carvajal-Carmona
    Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
    Hum Mol Genet 18:1889-92. 2009
    ..We, therefore, failed to replicate an association between common variants at ADIPOQ and CRC risk in the UK, and suggest that the previous report is either population-specific or a false-positive result...
  29. ncbi request reprint Two errors
    David J Kerr
    Department of Clinical Pharmacology, Radcliffe Infirmary, Oxford OX2 6HE, UK
    Lancet 364:907. 2004
  30. doi request reprint The challenge of cancer control in Africa
    Rebecca J Lingwood
    Department for Continuing Education, University of Oxford, Littlegate House, 16 17 St Ebbes street, Oxford, OX1 1PT, UK
    Nat Rev Cancer 8:398-403. 2008
    ..Many of these cancers are preventable, or treatable when detected early enough. Establishing effective, affordable and workable cancer control plans in African countries is one step in the right direction toward limiting this epidemic...
  31. doi request reprint Regional hepatic chemotherapies in the treatment of colorectal cancer metastases to the liver
    Thinn P Pwint
    Medical Oncology Unit, Churchill Hospital, Oxford, UK
    Semin Oncol 37:149-59. 2010
    ..The regional strategies reviewed include portal venous infusion (PVI) of 5-fluorouracil (5-FU), intra-arterial chemotherapy (hepatic arterial infusion [HAI]), chemoembolization, and selective internal radiation therapy (SIRT)...
  32. pmc Redesigning cancer care
    David Kerr
    Department of Clinical Pharmacology, Universityof Oxford, Radcliffe Infirmary
    BMJ 324:164-6. 2002
    ..The cancer services collaborative is using improvement methods to reduce delays and improve the service for patients. The nine cancer networks using these methods have cut waiting times and improved patients' experiences of care...
  33. pmc HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
    Omar Khan
    Laboratory of Cancer Biology, Medical Sciences Division, University of Oxford, Oxford OX3 7DQ, United Kingdom
    Proc Natl Acad Sci U S A 107:6532-7. 2010
    ..Our study supports the personalized medicine approach for treating cancer and the increasing drive to translate laboratory-based findings into clinical utility...
  34. doi request reprint Gene profiling in early stage disease
    Rachel Midgley
    Department of Clinical Pharmacology, University of Oxford, Headington, Oxford, UK
    Cancer J 16:210-3. 2010
    ..58; 95% CI, 1.15-2.15; P = 0.004). This may become established as a prognostic tool of choice for stage II colon cancer...
  35. ncbi request reprint NTRAC pioneering a virtual model
    David J Kerr
    National Translational Cancer Research Network, University of Oxford, Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, OX2 6HE, Oxford, UK
    Lancet Oncol 4:393. 2003
  36. ncbi request reprint CB 1954: from the Walker tumor to NQO2 and VDEPT
    Richard J Knox
    Enact Pharma PLC, Porton Down Scientific Park, Salisbury, Wiltshire, UK
    Curr Pharm Des 9:2091-104. 2003
    ..NQO2 activity is substantially raised in tumor samples from colorectal and hepatoma patients (up to 14-fold). A phase I clinical trial of an NQO2 co-substrate with CB 1954 is scheduled...
  37. ncbi request reprint Clinical experience with adenovirus in cancer therapy
    Daniel H Palmer
    CR UK Institute for Cancer Studies, The Medical School, University of Birmingham, Edgbaston, UK
    Curr Opin Mol Ther 4:423-34. 2002
    ..It is anticipated that adenovirus-mediated gene therapy will be integrated with existing treatment modalities, including surgery, chemotherapy and radiotherapy, to facilitate improvement in cancer treatments in the future...
  38. ncbi request reprint Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer
    Daniel H Palmer
    Cancer Research UK Institute for Cancer Studies, Department of Pathology and Liver Research Laboratories, University of Birmingham, UK
    J Clin Oncol 22:1546-52. 2004
    ..In this study, we report the first clinical trial investigating the feasibility, safety, and transgene expression of a replication-defective adenovirus encoding nitroreductase (CTL102) in patients with liver tumors...
  39. ncbi request reprint Nitroreductase: a prodrug-activating enzyme for cancer gene therapy
    Peter F Searle
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Edgbaston, Birmingham
    Clin Exp Pharmacol Physiol 31:811-6. 2004
    ..These can provide improved cell sensitization to CB1954. Combinations of these are being tested. 7. The basis for a positive selection for improved NTR variants has been demonstrated...
  40. ncbi request reprint Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
    Richard Gray
    Birmingham Clinical Trials Unit, University of Birmingham, Birmingham, UK
    Lancet 370:2020-9. 2007
    ..The aim of the QUASAR trial was to determine the size and duration of any survival benefit from adjuvant chemotherapy for patients with colorectal cancer at low risk of recurrence, for whom the indication for such treatment is unclear...
  41. ncbi request reprint Immunotherapy for colorectal cancer
    Rachel S Midgley
    Department of Health Clinician Scientist and Specialist Registrar Medical Oncology, Cancer Research UK, Churchill Hospital, Oxford
    Expert Rev Anticancer Ther 3:63-78. 2003
    ....
  42. ncbi request reprint Ras as a target in cancer therapy
    Rachel S Midgley
    CRC Institute for Cancer Studies, University of Birmingham, Birmingham, B15 2TT, Edgbaston, UK
    Crit Rev Oncol Hematol 44:109-20. 2002
    ..Though their clinical evaluation is still in infancy, these two modes of ras targeting represent rational therapeutic strategies that can undergo mechanistic evaluation in the clinic...
  43. ncbi request reprint Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway
    Paul M Taylor
    Cancer Research UK Institute for Cancer Studies, Birmingham University, Birmingham, B15 2TT, UK
    Oncogene 21:5765-72. 2002
    ..These results suggest that the production of soluble EMMPRIN, phospholipase A(2) and 5-lipoxygenase activities are sites for potential therapeutic intervention...
  44. ncbi request reprint Identification of FGF receptor-binding peptides for cancer gene therapy
    Fukuto Maruta
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, Birmingham B15 2TT, UK
    Cancer Gene Ther 9:543-52. 2002
    ..These peptides should provide useful ligands for specific delivery of gene therapy vectors to clinically relevant targets...
  45. ncbi request reprint Identification of an oligopeptide binding to hepatocellular carcinoma
    Akira Shimizu
    Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
    Oncology 71:136-45. 2006
    ..We carried out identification of a small peptide binding to human hepatocellular carcinoma (HCC) cells with the aim of applying the peptide for future HCC-targeted therapy or imaging...
  46. ncbi request reprint Single-dose clinical pharmacokinetic studies of gefitinib
    Helen C Swaisland
    AstraZeneca Pharmaceuticals, Macclesfield, UK
    Clin Pharmacokinet 44:1165-77. 2005
    ....
  47. ncbi request reprint Gene therapy for colorectal cancer
    Daniel H Palmer
    CRUK Institute for Cancer Studies, The Medical School, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TF, UK
    Br Med Bull 64:201-25. 2002
    ..It is likely that gene therapy will be integrated into pre-existing therapies including surgery, chemotherapy and radiotherapy to establish its niche in tomorrow's medicine...
  48. ncbi request reprint Use of a phage display library to identify oligopeptides binding to the lumenal surface of polarized endothelium by ex vivo perfusion of human umbilical veins
    Fukuto Maruta
    Cancer Research UK Institute for Cancer Studies, The University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    J Drug Target 11:53-9. 2003
    ..These initial peptides may prove useful targeting agents for endothelial-selective delivery, and this powerful approach should be readily applicable to biopanning in a broad range of human vessels ex vivo...
  49. ncbi request reprint A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer
    John P Neoptolemos
    Department of Surgery, Liverpool University, Liverpool, United Kingdom
    N Engl J Med 350:1200-10. 2004
    ..The effect of adjuvant treatment on survival in pancreatic cancer is unclear. We report the final results of the European Study Group for Pancreatic Cancer 1 Trial and update the interim results...
  50. ncbi request reprint Identification of oligopeptides binding to peritoneal tumors of gastric cancer
    Noriyuki Akita
    Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan
    Cancer Sci 97:1075-81. 2006
    ..The peptide motif KLP seems a potential targeting ligand for the treatment of peritoneal metastasis of gastric cancer...
  51. ncbi request reprint Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands
    Fukuto Maruta
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, and Department of Surgery, Selly Oak Hospital, UK
    J Drug Target 15:311-9. 2007
    ..This novel approach may be applicable to a wide range of settings, thus enabling iteration of consensus targeting sequences for tumour imaging and selective delivery of anticancer agents...
  52. ncbi request reprint Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin
    Leonard W Seymour
    Cancer Research UK Institute for Cancer Studies, University of Birmingham, United Kingdom
    J Clin Oncol 20:1668-76. 2002
    ..The present phase I study was devised to determine the toxicity, pharmacokinetic profile, and targeting capability of PK2...